
Tyra Biosciences (TYRA) Stock Forecast & Price Target
Tyra Biosciences (TYRA) Analyst Ratings
Bulls say
Tyra Biosciences is attractive fundamentally because its lead dabogratinib program is showing a convincing exposure-response relationship in FGFR3-altered bladder cancer, with 60mg QD delivering 57% 3-month CR and 64% best overall CR in the broader cohort, while safety has remained clean with no Grade 3 treatment-related AEs or discontinuations. The company’s cash position of $700.5M at 3Q26, together with the stated runway through 2030, reduces financing risk and supports multiple upcoming catalysts, including 2027 readouts in SURF302, SURF303, and BEACH301. Its pipeline also addresses large unmet-need settings such as adjuvant NMIBC, LG-UTUC, and achondroplasia, where higher dosing, favorable tolerability, and potentially broader efficacy could expand the commercial opportunity.
Bears say
Tyra Biosciences is viewed negatively because its lead assets still face material clinical and regulatory risk, with TYRA-300 potentially failing to show differentiated safety or efficacy and the broader pipeline needing to prove it can overcome the toxicity and resistance issues that limited first-generation pan-FGFR inhibitors. The company also appears vulnerable on commercial and revenue execution, while ABSK061’s baseline delta lacks a clean comparison to 52-week randomized ACH benchmarks, and Abbisko’s disclosure does not provide enough data to validate efficacy versus peer programs. Peer results from BridgeBio, Ascendis, and BioMarin underscore the bar Tyra must clear, and lavengratinib’s higher-dose 6-month data by YE26 would need to approach 5.9-6.0cm/year before BEACH301 can be viewed as truly competitive.
This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Tyra Biosciences (TYRA) Analyst Forecast & Price Prediction
Start investing in Tyra Biosciences (TYRA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Tyra Biosciences (TYRA) Forecast
Tyra Biosciences (TYRA) Analyst Forecast & Price Prediction
Start investing in Tyra Biosciences (TYRA)
Order type
Buy in
Order amount
Est. shares
0 shares